Exact sciences

Exact Sciences to Present Late-Breaking Data from ASCEND-2 Study Validating Its Investigational Multi-Cancer Early Detection Test at AACR Annual Meeting 2024

Retrieved on:

Monday, April 8, 2024

Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, will present late-breaking data from the first analysis of the ASCEND-2 study demonstrating the compelling performance of its investigational multi-biomarker class, multi-cancer early detection (MCED) blood test.

Key Points:

Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, will present late-breaking data from the first analysis of the ASCEND-2 study demonstrating the compelling performance of its investigational multi-biomarker class, multi-cancer early detection (MCED) blood test.
These results validate the sensitivity and specificity of the company’s multi-biomarker class approach across a broad range of cancer types, including the most aggressive cancers and cancers with no current standard of care for screening.
ASCEND-2 is a large, multi-center, prospective, case-control study of over 11,000 clinically characterized participants from a racially, ethnically, and geographically diverse cohort representative of the U.S. population.
Key findings: Results showed that in the rare instance when MCED testing detected pre-cancerous conditions in the DETECT-A study, surgical interventions prevented cancer development, and all patients were cancer-free at follow-up.

Fight Colorectal Cancer Unites Over 200 Advocates in Washington, D.C. for the 18th Annual Call-on Congress Event

Retrieved on:

Tuesday, March 12, 2024

JAMA, Colorectal cancer, Congress, Disease, Caregiver, Incidence, Ageing, Exact sciences, Research, Woman, Statistics, Survivor, CDC, CRC, Large intestine, Dairy

WASHINGTON, D.C., March 12, 2024 (GLOBE NEWSWIRE) -- In a powerful display of unity, Fight Colorectal Cancer (Fight CRC) is hosting the 18th Annual Call-on Congress event, bringing together over 200 colorectal cancer survivors, caregivers, and loved ones.

Key Points:

WASHINGTON, D.C., March 12, 2024 (GLOBE NEWSWIRE) -- In a powerful display of unity, Fight Colorectal Cancer (Fight CRC) is hosting the 18th Annual Call-on Congress event, bringing together over 200 colorectal cancer survivors, caregivers, and loved ones.
This landmark advocacy initiative aims to elevate personal stories and press for increased funding and support to combat colorectal cancer (CRC) .
Colorectal cancer, encompassing colon and rectal cancers, stands as the second-leading cause of cancer deaths for both men and women combined in the United States.
Encouraging Members of Congress to Champion Colorectal Cancer : Advocates will call on their representatives to become champions for colorectal cancer, actively working to transform the statistics surrounding the disease by joining the Colorectal Cancer Caucus.

Exact Sciences to Provide Mayo Clinic Patients with Individualized Cancer Tumor Information to Inform Treatment

Retrieved on:

Thursday, April 4, 2024

Exact Sciences (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced the launch of an initiative with Mayo Clinic to provide comprehensive genomic profiling and hereditary cancer tests to patients.

Key Points:

Exact Sciences (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced the launch of an initiative with Mayo Clinic to provide comprehensive genomic profiling and hereditary cancer tests to patients.
View the full release here: https://www.businesswire.com/news/home/20240404198461/en/
Initiative advances precision cancer medicine by bringing comprehensive genomic profiling and hereditary cancer tests to patients at the Mayo Clinic Comprehensive Cancer Center (Graphic: Business Wire)
“This collaboration supports our mission to help eradicate cancer by preventing it, detecting it earlier, and guiding personalized treatment,” said Kevin Conroy , chairman and chief executive officer, Exact Sciences.
The Riskguard hereditary cancer test helps patients and their physicians understand the patients' hereditary risk of cancer.
“It will also lead to new scientific and clinical discoveries by Mayo Clinic Comprehensive Cancer Center and Mayo Clinic's Center for Individualized Medicine .”
Patients will consent to have the tests performed and to have the data shared with Mayo Clinic.

Exact Sciences Advances Development of Non-Endoscopic Oncoguard® Esophagus Test to Screen for Esophageal Cancer and Pre-Cancer

Retrieved on:

Thursday, March 28, 2024

Other Health, Health, Science, Research, Oncology, Cancer, Incidence, Risk, Esophageal cancer, Patient, Education, Mayo Clinic, Hepatology, EAC, Exact sciences, DNA, MD, Division, HGD, FDA, Food, Medical device

“In collaborating with Exact Sciences, we are able to study the potential of a minimally invasive, non-endoscopic screening tool currently in development in patients at higher risk for EAC.

Key Points:

“In collaborating with Exact Sciences, we are able to study the potential of a minimally invasive, non-endoscopic screening tool currently in development in patients at higher risk for EAC.
“In esophageal cancer, earlier screening and detection will provide an important advance, as we have seen in other cancers.
We are collaborating with Mayo Clinic to continue the development of the Oncoguard Esophagus test as a minimally invasive solution for earlier detection of EAC and its precursors.”
The Oncoguard Esophagus test is currently under development and features of the test described above are outlining current development goals.
Mayo Clinic will use any revenue it receives to support its not-for-profit mission in patient care, education and research.

Exact Sciences Named 2024 Gallup Exceptional Workplace Award Winner

Retrieved on:

Wednesday, March 27, 2024

Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced it has received the 2024 Gallup Exceptional Workplace Award (GEWA).

Key Points:

Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced it has received the 2024 Gallup Exceptional Workplace Award (GEWA).
Gallup created the Exceptional Workplace Award to identify excellence and celebrate organizations that incorporate employee engagement into the bedrock of how they do their work, motivate their teams, and achieve business outcomes.
"Our sincere gratitude goes out to our amazing team at Exact Sciences who made winning the Gallup Exceptional Workplace recognition possible," said Sarah Condella, executive vice president of human resources at Exact Sciences.
Exact Sciences has also been awarded 2024 Top Workplace honors by USA Today and the Wisconsin State Journal, underscoring the company’s dedication to fostering a people-first workplace culture and prioritizing the employee experience.

The New England Journal of Medicine Publishes Cologuard Plus™ Test Results from Pivotal BLUE-C Study

Retrieved on:

Wednesday, March 13, 2024

“Cologuard Plus is highly sensitive for detecting colorectal cancer,” said Thomas F. Imperiale, MD, professor of medicine at the Indiana University School of Medicine, research scientist at the Regenstrief Institute, and principal investigator for the BLUE-C study.

Key Points:

“Cologuard Plus is highly sensitive for detecting colorectal cancer,” said Thomas F. Imperiale, MD, professor of medicine at the Indiana University School of Medicine, research scientist at the Regenstrief Institute, and principal investigator for the BLUE-C study.
BLUE-C investigators also collected blood samples for evaluation of a blood-based CRC screening test developed by Exact Sciences.
This enrollment diversity helps ensure that the BLUE-C findings and Cologuard Plus are relevant for all screen-eligible individuals, regardless of race or ethnicity.
ET to discuss results of the pivotal BLUE-C study.

Workflow Services Partners with Exact Sciences to Provide Colorectal Cancer Screening for Patients with Access Challenges at the Pharmacy

Retrieved on:

Friday, March 29, 2024

Biotechnology, EVP, Colorectal cancer, Partnership, Cancer, Patient, Pharmacy, American Cancer Society, Exact sciences, Pharmacist, Death, Risk, Exact Sciences (company)

MADISON, Wis., March 29, 2024 /PRNewswire/ -- Workflow Services, an automated platform that solves point-of-care clinical service delivery for pharmacies, announced a new agreement with Exact Sciences, a biotechnology company that develops tests designed to prevent, detect, and guide the successful treatment of cancer. This new partnership brings the power of the Workflow Services platform—a full spectrum, front-to-back digital solution supporting point-of-care service delivery—to help educate eligible patients who visit the pharmacy on the importance of having a colorectal cancer screening.

Key Points:

This new partnership brings the power of the Workflow Services platform—a full spectrum, front-to-back digital solution supporting point-of-care service delivery—to help educate eligible patients who visit the pharmacy on the importance of having a colorectal cancer screening.
When detected at an early stage, colorectal cancer, the second leading cause of death from cancer in the U.S., is highly treatable in about 90% of cases*.
In this new approach, pharmacists are empowered to use the Workflow Services platform to educate patients about colorectal cancer screening options.
To learn more about colorectal cancer screening, visit Exact Sciences .

United in the Fight Against Colorectal Cancer

Retrieved on:

Thursday, March 7, 2024

Breast cancer, Incidence, American Cancer Society, Woman, Amgen, ACS, CRC, Patient, Mortality, Colorectal cancer, Research, Exact sciences

A recent report from the American Cancer Society (ACS) underscores the urgent need for action, revealing alarming trends: colorectal cancer is now the leading cause of cancer-related deaths in men under 50 and second among young women, trailing only breast cancer.

Key Points:

A recent report from the American Cancer Society (ACS) underscores the urgent need for action, revealing alarming trends: colorectal cancer is now the leading cause of cancer-related deaths in men under 50 and second among young women, trailing only breast cancer.
Despite these escalating rates, there has been a lack of progress in developing effective treatment options for colorectal cancer patients, and persistent health disparities in incidence, mortality, and survivorship rates continue to exist.
United in Blue serves as a visual reminder for policymakers, emphasizing the necessity of increasing research funding for colorectal cancer and implementing a comprehensive plan to address the needs of the community.
Fight CRC’s United in Blue installation is sponsored by Amgen and Exact Sciences.

Exact Sciences and Basketball Great Jamal Mashburn Encourage Americans 45+ to Have a Game Plan Against Colon Cancer

Retrieved on:

Thursday, March 7, 2024

Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, is teaming up with iconic pro basketball all-star and Kentucky legend Jamal Mashburn to introduce "Box Out Colon Cancer," in observance of Colorectal Cancer Awareness Month and the most exciting time in college basketball.

Key Points:

Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, is teaming up with iconic pro basketball all-star and Kentucky legend Jamal Mashburn to introduce "Box Out Colon Cancer," in observance of Colorectal Cancer Awareness Month and the most exciting time in college basketball.
View the full release here: https://www.businesswire.com/news/home/20240307418330/en/
Basketball great Jamal Mashburn is spreading the word about the importance of colorectal cancer screening beginning at age 45 with the "Box Out Colon Cancer" campaign.
(Photo: Business Wire)
“Box Out Colon Cancer” is a direct response to the alarming, increasing rates of colon cancer diagnoses and deaths under the age of 50.3 With support from Mashburn, “Box Out Colon Cancer” is issuing a challenge to some of the nation’s leading college basketball coaches – over the age of 45 – asking them to get screened for colon cancer and encouraging others to do the same.
“Both with basketball and colon cancer, the best defense is a good offense,” says Mashburn, who took up the cause in loving memory of his mother, Helen, who battled colon cancer in her lifetime.

Exact Sciences Launches Riskguard™ Hereditary Cancer Test in the United States

Retrieved on:

Wednesday, February 28, 2024

Exact Sciences Corp., a leading provider of cancer screening and diagnostic tests, today announced the launch of the Riskguard™ hereditary cancer test in the United States.

Key Points:

Exact Sciences Corp., a leading provider of cancer screening and diagnostic tests, today announced the launch of the Riskguard™ hereditary cancer test in the United States.
Offering more effective personalized screening solutions supports Exact Sciences’ commitment to help detect cancer earlier.”
For patients already diagnosed with cancer, knowing about certain gene variants can help create individualized treatment plans for patients.
Exact Sciences’ customer care teams are available to help patients explore the testing process and understand possible results and outcomes.
The test is processed in Marshfield, WI at PreventionGenetics, an Exact Sciences laboratory qualified to perform high-complexity clinical laboratory testing that has been providing quality genetic testing since 2004 and joined Exact Sciences in 2022.